Key result
Review outlines recent advances in triglyceride-rich lipoprotein metabolism and available treatments for hypertriglyceridemia.
Why the study?
Evidence supports a causal relationship between triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease, underscoring the importance of understanding the molecular mechanisms and regulation of VLDL and chylomicron biogenesis and metabolism.
This review summarizes recent advances in the understanding of triglyceride-rich lipoprotein metabolism and available treatment strategies for hypertriglyceridemia.
Recent advances in human genetics, together with a substantial body of epidemiological, preclinical and clinical trial evidence, strongly support a causal relationship between triglyceride-rich lipoproteins (TRLs) and atherosclerotic cardiovascular disease. Consequently, the secretion and metabolism of TRLs have a significant impact on cardiovascular health. This knowledge underscores the importance of understanding the molecular mechanisms and regulation of very-low-density lipoprotein (VLDL) and chylomicron biogenesis. Fortunately, there has been a resurgence of interest in the intracellular assembly, trafficking, degradation, and secretion of VLDL, leading to many ground-breaking molecular insights. Furthermore, the identification of molecular control mechanisms related to triglyceride metabolism has greatly advanced our understanding of the complex metabolism of TRLs. In this review, we explore recent advances in the assembly, secretion, and metabolism of TRLs. We also discuss available treatment strategies for hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Borén et al. (2024) conducted a review in Hypertriglyceridemia. This review explores recent advances in the assembly, secretion, and metabolism of triglyceride-rich lipoproteins and discusses available treatment strategies for hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: